logo-loader
Deep diveHealth
Redx Pharma Plc

Redx Pharma: Developing treatments for cancer and fibrosis

Snapshot

Its lead asset, RXC004, is part of a potentially breakthrough group of cancer drugs called Porcupine inhibitors

researcher at microscope

Quick facts: Redx Pharma Plc

Price: £0.09

Market: AIM
Market Cap: £10.75 m
Follow
  • Cancer drug in the clinic 
  • Promising fibrosis treatments targeting large markets

What the company does 

Redx Pharma Plc (LON:REDX) is an early-stage drug developer that is bringing through treatments for cancer and fibrosis.

Its lead asset, RXC004, is part of a potentially breakthrough group of cancer drugs called Porcupine inhibitors. They work by dialling down the Porcupine protein, which is the control switch for the Wnt pathway – known to be heavily involved in cell growth and division. Now, not all cancers are driven by the Wnt pathway, but the hope is that RXC004 will inhibit the growth of those which are.

Interestingly, there’s a growing bank of research that suggests Porcupine inhibitors may also be very effective in tandem with checkpoint inhibitors such as anti-PD-1s, which lower or break cancer’s defence against the body’s immune system. That’s why Redx plans to assess the drug in combination with a checkpoint inhibitor further down the line, something Swiss giant Novartis is doing with its Porcupine inhibitors.

In parallel it is developing potential fibrosis treatments. RXC006 is designed to tackle a condition called idiopathic pulmonary fibrosis (IPF), a type of chronic lung disease. ROCK2 has been developed to treat non-alcoholic liver disease, while it is also targeting Crohn’s Disease-related fibrosis.

RXC004

After a false start, Redx is resuming its phase I clinical trial. The trial is split in two: phases Ia and Ib. The former is focused on finding the safest most effective dose, while the latter will seek efficacy data.  The phase Ia will take place over the next 12-18 months, working with advanced cancer patients. The lead investigator is Dr Natalie Cook, of the Christie Hospital, Manchester. The other centres are The Marsden and Guys (London), Oxford and Newcastle.

Value kickers

  • RXC004 Ib-ready in the first-half of next year
  • Fibrosis treatments target significant commercial markets
  • Phase 1-ready idiopathic pulmonary fibrosis candidate ready to enter clinic in the next year

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Redx Pharma Plc named herein, including the promotion by the Company of Redx Pharma Plc in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

'It's a particularly exciting time for Redx Pharma' - Capital Network's...

Capital Network's Healthcare Analyst Riccardo Lowi gives his view on Redx Pharma Plc (LON:REDX). ''The reason it's a particularly exciting time for the company is because they're moving  their two lead candidates into the clinical stage, it's the first time they're moving a drug...

on 04/03/2017

2 min read